Cadrenal Therapeutics, Inc. Financial Overview
Cadrenal Therapeutics, Inc.'s market cap is currently $16.62M. The company's EPS TTM is $-1.31; its P/E ratio is -0.89; Cadrenal Therapeutics, Inc. is scheduled to report earnings on November 10, 2025, and the estimated EPS forecast is $-1.21. See an overview of income statement, balance sheet, and cash flow financials.
